GLUE
Monte Rosa Therapeutics, Inc.
Biotechnology
Market Cap$1.11B
5Y Perf.-24.7%
Build Your Comparison
Side-by-side financial analysisGLUE
BEAM
Try popular comparisons:
Stock Comparison
GLUE vs BEAM
Revenue, margins, valuation, and 5-year total return — side by side.
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.02B
5Y Perf.-77.2%
GLUE vs BEAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  GLUE |  BEAM |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.11B | $3.02B |
| Revenue (TTM) | $43M | $132M |
| Net Income (TTM) | $-130M | $-65M |
| Gross Margin | 95.3% | -64.2% |
| Operating Margin | -345.2% | -281.0% |
| Total Debt | $39M | $294M |
| Cash & Equiv. | $130M | $295M |
GLUE vs BEAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GLUE
BEAM
| Stock | Jun 21 | Jun 26 | Return |
|---|---|---|---|
| Monte Rosa Therapeu… (GLUE) | 100 | 75.3 | -24.7% |
| Beam Therapeutics I… (BEAM) | 100 | 22.8 | -77.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GLUE vs BEAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BEAM leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Monte Rosa Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇BEAM emerged as the overall leader. Track its performance:
GLUE
Monte Rosa Therapeutics, Inc.
The Income Pick
GLUE is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.30
- Lower volatility, beta 1.30, Low D/E 16.8%, current ratio 6.12x
- Beta 1.30, current ratio 6.12x
Best for: income & stability and sleep-well-at-night
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 56.9% 10Y total return vs GLUE's -19.3%
- 120.0% revenue growth vs GLUE's 63.5%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  BEAM | 120.0% revenue growth vs GLUE's 63.5% |
| Quality / Margins | BEAM | -49.2% margin vs GLUE's -302.7% |
| Stability / Safety |  GLUE | Beta 1.30 vs BEAM's 2.27, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | GLUE | +238.6% vs BEAM's +64.4% |
| Efficiency (ROA) | BEAM | -4.6% ROA vs GLUE's -25.9%, ROIC -31.1% vs -44.2% |
GLUE vs BEAM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGLUELAGGINGBEAM
BEAMBeam Therapeutics Inc.
0leads
GLUEMonte Rosa Therapeuti…
3leads
6 Total Categories
CATEGORYLEADERvs BEAMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
GLUE2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GLUE5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
GLUE5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — GLUE and BEAM each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BEAM is the larger business by revenue, generating $132M annually — 3.1x GLUE's $43M. Profitability is closely matched — net margins range from -49.2% (BEAM) to -3.0% (GLUE). On growth, GLUE holds the edge at -95.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GLUEMonte Rosa Therap… | BEAMBeam Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $43M | $132M |
| EBITDAEarnings before interest/tax | -$140M | -$355M |
| Net IncomeAfter-tax profit | -$130M | -$65M |
| Free Cash FlowCash after capex | -$20M | -$384M |
| Gross MarginGross profit ÷ Revenue | +95.3% | -64.2% |
| Operating MarginEBIT ÷ Revenue | -3.5% | -2.8% |
| Net MarginNet income ÷ Revenue | -3.0% | -49.2% |
| FCF MarginFCF ÷ Revenue | -45.8% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -95.0% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +26.6% |
Evenly matched — GLUE and BEAM each lead in 3 of 6 comparable metrics.
Valuation Metrics
GLUE leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | GLUEMonte Rosa Therap… | BEAMBeam Therapeutics… |
|---|---|---|
| Market CapShares × price | $1.1B | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $1.0B | $3.0B |
| Trailing P/EPrice ÷ TTM EPS | -37.17x | -36.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.00x | 21.62x |
| Price / BookPrice ÷ Book value/share | 6.10x | 2.35x |
| Price / FCFMarket cap ÷ FCF | — | — |
GLUE leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
GLUE leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
BEAM delivers a -5.9% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-41 for GLUE. GLUE carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to BEAM's 0.24x. On the Piotroski fundamental quality scale (0–9), GLUE scores 6/9 vs BEAM's 4/9, reflecting solid financial health.
| Metric | GLUEMonte Rosa Therap… | BEAMBeam Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | -41.0% | -5.9% |
| ROA (TTM)Return on assets | -25.9% | -4.6% |
| ROICReturn on invested capital | -44.2% | -31.1% |
| ROCEReturn on capital employed | -16.3% | -33.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.17x | 0.24x |
| Net DebtTotal debt minus cash | -$91M | -$1M |
| Cash & Equiv.Liquid assets | $130M | $295M |
| Total DebtShort + long-term debt | $39M | $294M |
| Interest CoverageEBIT ÷ Interest expense | — | 1.08x |
GLUE leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
GLUE leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GLUE five years ago would be worth $8,074 today (with dividends reinvested), compared to $3,313 for BEAM. Over the past 12 months, GLUE leads with a +238.6% total return vs BEAM's +64.4%. The 3-year compound annual growth rate (CAGR) favors GLUE at 35.7% vs BEAM's -3.7% — a key indicator of consistent wealth creation.
| Metric | GLUEMonte Rosa Therap… | BEAMBeam Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | +11.7% | +8.4% |
| 1-Year ReturnPast 12 months | +238.6% | +64.4% |
| 3-Year ReturnCumulative with dividends | +149.6% | -10.8% |
| 5-Year ReturnCumulative with dividends | -19.3% | -66.9% |
| 10-Year ReturnCumulative with dividends | -19.3% | +56.9% |
| CAGR (3Y)Annualised 3-year return | +35.7% | -3.7% |
GLUE leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GLUE and BEAM each lead in 1 of 2 comparable metrics.
Risk & Volatility
GLUE is the less volatile stock with a 1.30 beta — it tends to amplify market swings less than BEAM's 2.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BEAM currently trades 80.7% from its 52-week high vs GLUE's 66.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GLUEMonte Rosa Therap… | BEAMBeam Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.30x | 2.27x |
| 52-Week HighHighest price in past year | $25.77 | $36.44 |
| 52-Week LowLowest price in past year | $4.12 | $15.60 |
| % of 52W HighCurrent price vs 52-week peak | +66.4% | +80.7% |
| RSI (14)Momentum oscillator 0–100 | 36.4 | 48.7 |
| Avg Volume (50D)Average daily shares traded | 818K | 1.9M |
Evenly matched — GLUE and BEAM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates GLUE as "Buy" and BEAM as "Buy". Consensus price targets imply 85.7% upside for GLUE (target: $32) vs 63.2% for BEAM (target: $48).
| Metric | GLUEMonte Rosa Therap… | BEAMBeam Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $31.75 | $48.00 |
| # AnalystsCovering analysts | 9 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
GLUE leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 2 categories are tied.
Best OverallMonte Rosa Therapeutics, In… (GLUE)Leads 3 of 6 categories
Loading custom metrics...
GLUE vs BEAM: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is GLUE or BEAM a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus 63. 5% for Monte Rosa Therapeutics, Inc. (GLUE). Analysts rate Monte Rosa Therapeutics, Inc. (GLUE) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GLUE or BEAM?
Over the past 5 years, Monte Rosa Therapeutics, Inc.
(GLUE) delivered a total return of -19. 3%, compared to -66. 9% for Beam Therapeutics Inc. (BEAM). Over 10 years, the gap is even starker: BEAM returned +56. 9% versus GLUE's -19. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GLUE or BEAM?
By beta (market sensitivity over 5 years), Monte Rosa Therapeutics, Inc.
(GLUE) is the lower-risk stock at 1. 30β versus Beam Therapeutics Inc. 's 2. 27β — meaning BEAM is approximately 74% more volatile than GLUE relative to the S&P 500. On balance sheet safety, Monte Rosa Therapeutics, Inc. (GLUE) carries a lower debt/equity ratio of 17% versus 24% for Beam Therapeutics Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — GLUE or BEAM?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus 63. 5% for Monte Rosa Therapeutics, Inc. (GLUE). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to 53. 1% for Monte Rosa Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GLUE or BEAM?
Monte Rosa Therapeutics, Inc.
(GLUE) is the more profitable company, earning -31. 2% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps -31. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GLUE leads at -43. 8% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — GLUE leads at 93. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — GLUE or BEAM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GLUE or BEAM better for a retirement portfolio?
For long-horizon retirement investors, Monte Rosa Therapeutics, Inc.
(GLUE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 27 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GLUE: -19. 3%, BEAM: +56. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GLUE and BEAM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.